American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
about
Oral budesonide for induction of remission in ulcerative colitisEtrolizumab for induction of remission in ulcerative colitisEtrolizumab for induction of remission in ulcerative colitisAnti-MAdCAM antibody for induction of remission in ulcerative colitisAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisTacrolimus (FK506) for induction of remission in refractory ulcerative colitisTraditional corticosteroids for induction of remission in Crohn's diseaseAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisPromising biological therapies for ulcerative colitis: A review of the literatureMesalamine in the treatment and maintenance of remission of ulcerative colitisUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Preventive health measures in inflammatory bowel diseaseDietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γAssessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendationsThe diagnosis and treatment of Crohn's disease and ulcerative colitisHealthcare maintenance in elderly patients with inflammatory bowel disease.Current approaches to the management of new-onset ulcerative colitis.Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.European evidence-based Consensus on the management of ulcerative colitis: Current management.Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.Methotrexate: underused and ignored?Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitorPros and cons of medical management of ulcerative colitis.Infliximab to treat Crohn's disease: an update.Managing refractory Crohn's disease: challenges and solutionsPatterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study.Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.Emerging drugs for the treatment of ulcerative colitisUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Andrographis paniculata extract (HMPL-004) for active ulcerative colitis.Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.Review and clinical perspectives for the use of infliximab in ulcerative colitis.
P2860
Q24186368-759BA8B8-3D9A-4E00-9C05-29C9F7C7EF36Q24186788-0EDA2116-1184-4FC3-B8A7-87249D1596E2Q24187269-857907DB-680D-4BC3-83F2-31F68280D8C2Q24187593-88E973E4-A762-49FA-86E6-4553E8C077E9Q24200757-F23F427A-DB49-4DD4-8EB6-35B3BD8D9C7EQ24242681-4D071F8B-E356-4C6D-B88A-2D0278B932BDQ24242955-44AC3BCA-C728-4BB3-B8B6-A0C64A1414A5Q24243219-AF078DE9-BB25-4DBC-AB1A-0089D20D578CQ26776139-A2426B77-C6BE-4433-BB4C-05D652720D36Q26865546-C7C539A2-1E26-42CF-ADEE-029A5ECA8B4BQ26996946-CB1FBEAE-3BAF-4B85-B618-96900CAB8B3CQ27005716-E26FD124-DEFF-457D-86DE-EDF434948BB4Q27021612-993DECF9-50FB-4860-A08E-75A06874C559Q27687191-CBEFD9F1-083B-4523-9A72-5821F4E235DBQ28078112-55057AC0-0621-4C85-ACCB-22B9941A8FE9Q28476741-C6CF807F-D621-4FB0-BD5B-72B3D2F89900Q31146183-A497D78D-A3C0-4645-8A99-0E3A7D718FE6Q33385516-A1836A73-D4E7-4F07-A090-3FE42AA21A50Q33476811-20A8E8AA-89D5-421A-83EA-611BCB85DD09Q33621700-32ABCB58-8F5B-43E9-9819-BA897F982339Q33633288-5B738A3A-E3CF-4D9D-AB50-FBAC1FFB1ED7Q33879437-B680BA47-C00E-4276-9C64-E643982830F8Q33882852-D3B5BB74-09F8-4EC2-BFB2-B526E7D36F61Q34025054-9693BFB5-E82C-46E5-B2CE-A4BA43BD58ACQ34303155-81AE7FBC-6EB2-4956-BDBA-565110A0804CQ34321255-D4D0928F-E553-46EB-843C-D764CF3D3D40Q34367007-91B4C370-120E-4A7C-8D5B-086A0A7B5FADQ35057027-D65D10FF-89AB-4768-82EE-ACADDA1F643BQ35100726-96EE55A6-F89E-4264-BB2E-D4DA7DDB9B9AQ35304737-0ADA1CEE-966F-4427-99CF-1DA36FB13890Q35460367-E61C71AB-B1B7-47D8-9119-AA1CAB7D1340Q35752421-AA8CA01F-4F02-4FD8-B2F6-0A225FE748AFQ35791848-8958CB0C-E786-4D1B-B24A-C6A3149FDFCDQ36009845-F5254F89-DC8F-4313-8BFB-18AD6FEC5051Q36039436-4B223F39-9137-4526-A6C3-07177557A5ECQ36144377-B3CF6E2F-B4AB-4D2A-AC9A-D3BD456B31DCQ36372720-15EEC37A-794E-49CE-852C-F9F16658D73DQ36512022-0DF9B021-0197-4A8C-86C8-222C80730C33Q36919671-5509AF1D-85EE-47F2-B65C-59CE86968969Q37114650-3524D1FC-C825-41FA-9CB7-912B5BAD23C9
P2860
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
American Gastroenterological A ...... in inflammatory bowel disease.
@ast
American Gastroenterological A ...... in inflammatory bowel disease.
@en
type
label
American Gastroenterological A ...... in inflammatory bowel disease.
@ast
American Gastroenterological A ...... in inflammatory bowel disease.
@en
prefLabel
American Gastroenterological A ...... in inflammatory bowel disease.
@ast
American Gastroenterological A ...... in inflammatory bowel disease.
@en
P2093
P921
P1433
P1476
American Gastroenterological A ...... in inflammatory bowel disease.
@en
P2093
Gary R Lichtenstein
Maria T Abreu
Russell Cohen
P304
P356
10.1053/J.GASTRO.2006.01.048
P407
P577
2006-03-01T00:00:00Z